New Risk • Jun 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (kr4.2m revenue, or US$441k). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Annuncio • Jun 04
DexTech Medical AB Reports Positive Preliminary Results From Fully Recruited Myeloma Study With OsteoDex DexTech Medical AB conducted a study at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment has lasted for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) have been studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Adult myeloma patients with, according to IMWG (International Myeloma Working Group) criteria, progressive treatment-resistant disease, who had previously received 1-5 lines of treatment were included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. The last patient in dose group 2 (6mg/kg) was fully treated week 50, 2025 (7 doses). The patient continued to have stable, i.e. non-progressive, disease just over 5 months after the end of treatment and before new progress resumed. All patients in dose group 3 (9mg/kg) had achieved stable (non-progressive) disease after discontinuation of treatment at the end of February. The patients have continued to maintain non-progressive disease at the end of May. No significant ODX-related adverse events have been noted. Thus, no induced toxicity on organ systems, such as kidneys, liver, or bone marrow. Primary endpoint has been met, with the absence of significant ODX-related toxicity. The results also show that all patients responded positively to ODX treatment, with a transition from progressive (according to IMWG criteria) to non-progressive disease during ODX treatment. More than 70% of the patients maintained their achieved stable, non-progressive, disease even after the ODX treatment was discontinued. This is consistent with the mechanism of action, i.e. significant enrichment of ODX in the myeloma areas of the skeleton. The patients in dose group 3 are now being followed continuously (>June) until new disease progression, which is why the completion of the CSR (clinical study report) is postponed until all results from the extended follow-up are available. The company has analyzed all clinical data, including the prostate cancer studies (mCRPC), and finds the effects of the same mode of action (MOA) in both mCRPC and multiple myeloma. Simply described, ODX rapidly changes/modifies the tumor cells' microenvironment and thereby impairs their breeding ground and the conditions for continued growth (progression). The mechanism is unique to ODX as an anticancer drug and has very interesting implications for the treatment of other cancers with bone involvement, e.g. breast cancer. The absence of ODX-related toxicity opens up great opportunities for combination therapies (very common in modern cancer treatment) without adding toxicity. Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. No independent directors (6 non-independent directors). Director Peter Benson was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annuncio • Jan 27
DexTech Medical Ab's Myeloma Study, Completes At the End of February 2026, Concludes with Continued Strong Results DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. The last patient in dose group 2 (6mg/kg) was finished in week 50 (7 doses) and has had his last visit. The patient then continued to have stable disease. All patients in dose group 3 (9mg/kg) have achieved stable disease and will be completed by the end of February. No significant ODX related side effects have been noted. Patients with stable disease after completion of ODX treatment are followed until new progress to map how long the disease-inhibiting effect persists. Data obtained so far show that the disease-inhibiting effects in some cases persists for months and at most up to six months without initiation of other cancer treatment. The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease. Annuncio • Dec 05
DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive, treatment-resistant, disease, who have previously received 1-5 prior lines of treatment are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. The last patient in dose group 2 (6mg/kg) is expected to be finished at week 50 (7 doses). After 6 doses, the patient has still maintained their achieved stable disease, i.e. the progression verified prior to the start of treatment has stopped. The other 3 patients in dose group 2 have, after completion of ODX treatment and the disease was stable, now returned to their progressive disease. The first patient in dose group 3 (9mg/kg) has received 3 doses to date. Here, too, the progressive disease has turned into a stable one. A further 2 patients in dose group 3 have only recently started their ODX treatment. This means that so far, 9/9 (100%) of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). The patients are followed as planned after completion of ODX treatment; this is to map when the disease progresses again. The disease-inhibiting effect persists in some cases even after postponed ODX treatment, at most up to six months. Annuncio • Oct 17
DexTech Medical's Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3 DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. Dose group 2 (6mg/kg) has been fully recruited. Two patients in dose group 2 have progressive disease after completion of treatment. The other 2 patients will finish the treatment in early December. The DMC (Independent Data Monitoring Committee) approves the continuation to dose group 3. No ODX related serious side effects have been noted. A new patient for dose group 3 has been screened. Follow-up of all patients who have achieved stable disease is done to determine how long the disease-slowing effect persists after the ODX treatment has been discontinued, i.e., until new progress. Annuncio • Aug 21
DexTech Medical AB Announces Study of ODX Treatment for Adult Myeloma Patients with Progressive Treatment-Resistant Disease DexTech Medical AB announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital". Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. Dose group 2 (6mg/kg) is expected to be fully recruited in August/September. Two patients in dose group 2 have progressive disease after completion of treatment. This means that so far, 67% of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). No significant, ODX-related, side effects have been noted. Follow-up of all patients who have achieved stable disease is done to determine how long the disease-inhibiting effect persists after the ODX treatment has been discontinued. Follow-up of patients from dose group 1 shows that the disease-inhibiting impact continued, even after discontinuation of ODX. At most, the disease-inhibiting effects lasted just over six months without the initiation of other cancer treatment. A meeting of the DMC (the independent data monitoring committee) is expected to be held in September to approve the continuation to dose group 3. Annuncio • May 21
Dextech Medical's Patent Application Regarding Gmp Manufacturing of Osteodex is approved OsteoDex is DexTech's lead candidate for the treatment of castration-resistant prostate cancer and has completed clinical phase 2. In October 2023, the Company filed a patent application with the EPO (European patent office, application No. 23203437.1). The application concerned GMP (Good Manufacturing Practice) manufacturing of OsteoDex. The application has now been approved, and a patent has been granted. The patent is of great importance for the continued clinical development of OsteoDex and future market exclusivity. The patent is valid until 2045 and is very positive for the Company's partnership/out-licensing talks. Annuncio • Apr 23
DexTech Medical AB's Myeloma Study, Strong Follow-Up Results DexTech Medical AB announced that the study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment boasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed treatment-resistant disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine indications of treatment response. The follow-up shows interesting results. At the first follow-up after completion of treatment, all patients in dose group 1, (four patients, 3mg/kg) have stable disease. The patients have then been followed, without other cancer treatment, until new progression of the disease (according to the amendment). Time to progress was 89 days, 59 days, 188 days and 39 days. None of the patients had any significant side effects from the ODX treatment. The results indicate that ODX is effective against multiple myeloma and that the slowing effect remains over time without other treatment. Reported Earnings • Oct 25
First quarter 2025 earnings released: kr0.062 loss per share (vs kr0.05 loss in 1Q 2024) First quarter 2025 results: kr0.062 loss per share (further deteriorated from kr0.05 loss in 1Q 2024). Revenue: kr585.0k (down 65% from 1Q 2024). Net loss: kr1.14m (loss widened 24% from 1Q 2024). Reported Earnings • Sep 26
Full year 2024 earnings released: kr0.25 loss per share (vs kr0.25 loss in FY 2023) Full year 2024 results: kr0.25 loss per share (in line with FY 2023). Revenue: kr5.39m (down 38% from FY 2023). Net loss: kr4.71m (loss widened 2.5% from FY 2023). Annuncio • Sep 25
Dextech Medical AB to Report Q1, 2025 Results on Oct 24, 2024 Dextech Medical AB announced that they will report Q1, 2025 results on Oct 24, 2024 Annuncio • Aug 13
Dextech Medical AB Announces Continued Positive Results from Myeloma Study Dextech Medical AB announced continued positive results from myeloma study. The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready, and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. Three out of four patients have stable disease after completion of treatment (stable = no progression of the disease). Patients with stable disease will be followed up until new progress according to the approved amendment, which provides information on how long the treatment effect lasts. The study includes up to a maximum of 20 patients and is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. More hospitals may be involved later. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) treatment-resistant disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine treatment response. The study is expected to be completed in Q2, 2025. New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (kr5.4m revenue, or US$515k). Market cap is less than US$10m (€6.79m market cap, or US$7.33m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Apr 28
Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023) Third quarter 2024 results: kr0.077 loss per share (improved from kr0.079 loss in 3Q 2023). Revenue: kr1.26m (down 59% from 3Q 2023). Net loss: kr1.42m (loss narrowed 3.2% from 3Q 2023). Annuncio • Apr 16
DexTech Medical Announces New Positive Results from the Myeloma Study DexTech Medical AB announced new positive results from the myeloma study. The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). progressive disease means that the disease progresses and does not respond to existing treatment. A patient who has shown a sharp reduction in skeletal biomarkers and who has now completed his treatment is found to have stable disease with continued low values of markers that reflect skeletal activity. Stable disease means that the disease does not develop/progress, which is very positive. The company now intends to follow patients with stable disease for up to 2 years after completion of OsteoDex treatment. A so-called amendment has been submitted to the relevant authorities. The follow-up provides the Company with valuable information about how long OsteoDex's effect lasts. The study covers a total of max. 20 patients and is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. More hospitals may be involved at a later date. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. The recruitment of patients is relatively slow (competing studies, inclusion requirements), which means that the conclusion of the study is postponed somewhat to second quarter, 2025. This means that study costs are also postponed, which means that the Company is financed throughout 2025. New Risk • Apr 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.31m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (kr7.3m revenue, or US$676k). Market cap is less than US$10m (€9.31m market cap, or US$9.99m). Reported Earnings • Feb 16
Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023) Second quarter 2024 results: kr0.058 loss per share (improved from kr0.065 loss in 2Q 2023). Revenue: kr879.0k (down 71% from 2Q 2023). Net loss: kr1.08m (loss narrowed 9.9% from 2Q 2023). Annuncio • Jan 24
Dextech Medical AB Announces Positive Results from the Myeloma Study DexTech Medical AB announced positive results from the myeloma study. The first test results from patient 1 have been received and show a very strong effect on the marker of osteoDex. The baseline value for CTX decreases by about 80% after 3 doses of OsteoDex. The other values are fairly constant (cf. baseline). Osteoclasts break down bone (resorb) and CTX reflects osteoDex activity that is elevated in multiple myeloma. The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Sodersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dratarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (pro progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. The study is expected to be completed in fourth quarter, 2024. Annuncio • Dec 13
DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated DexTech Medical AB announced that the Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Sodersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dratarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (pro progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. Biochemical markers are continuously analyzed, and the first assay results are expected in first quarter-24. The study is expected to be completed in fourth quarter, 2024. The work to seek partnerships regarding continued clinical development of OsteoDex - mCRPC towards phase 3 - is ongoing. The Company's synthesis patent application, filed with the European Patent Office (EPO.org) in October -23, is of great importance for the Company's opportunities for partnership as well as positive results from the Company's MM study. The conditions for the patent application to be granted are good, resulting in market exclusivity until 2044. Without consulting the results from the MM study, Osteodex's positive effect on bone-degrading bone cells and the absence of serious side effects are well documented and will probably be confirmed in the MM study as well. Reported Earnings • Oct 29
First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023) First quarter 2024 results: kr0.05 loss per share (further deteriorated from kr0.044 loss in 1Q 2023). Revenue: kr1.65m (up 75% from 1Q 2023). Net loss: kr917.0k (loss widened 13% from 1Q 2023). Annuncio • Sep 29
Dextech Medical AB, Annual General Meeting, Oct 31, 2023 Dextech Medical AB, Annual General Meeting, Oct 31, 2023, at 10:00 Central European Standard Time. Location: IVA's conference centre, Kungl Royal Swedish Academy of Engineering Sciences, Grev Turegatan 16, Stockholm Stockholm Sweden Agenda: To consider resolution on adoption of the profit and loss account and balance sheet; to consider resolution on the appropriation of the company's profit or loss in accordance with the adopted balance sheet; and to consider other items. Board Change • Sep 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Peter Benson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Peter Benson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.